A placebo-controlled trial of Korean red ginseng extract for preventing influenza-like illness in healthy adults - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1186/1472-6882-12-10.

Min-Gul Kim, Mi-Ra Oh, Eun-Kyung Choi, Hyang-Im Back, Sun-Young Kim, Eun-Ok Park, Dae-Young Kwon, Hye-Jeong Yang, Min-Jeong Kim, Hee-Joo Kang, Ju-Hyung Lee, Kyung-Min Choi, Soo-Wan Chae, Chang-Seop Lee

Affiliations

Randomized Controlled Trial

A placebo-controlled trial of Korean red ginseng extract for preventing influenza-like illness in healthy adults

Ki-Chan Ha et al. BMC Complement Altern Med. 2012.

Abstract

Background: Standardized Korean red ginseng extract has become the best-selling influenza-like illness (ILI) remedy in Korea, yet much controversy regarding the efficacy of the Korean red ginseng (KRG) in reducing ILI incidence remains. The aim of the study is to assess the efficacy of the KRG extract on the ILI incidence in healthy adults.

Methods/design: We will conduct a randomized, double-blind, placebo-controlled study at the onset of the influenza seasons. A total of 100 subjects 30-70 years of age will be recruited from the general populations. The subjects will be instructed to take 9 capsules per day of either the KRG extract or a placebo for a period of 3 months. The primary outcome measure is to assess the frequency of ILI onset in participated subjects. Secondary variable measures will be included severity and duration of ILI symptoms. The ILI symptoms will be scored by subjects using a 4-point scale.

Discussion: This study is a randomized placebo controlled trial to evaluate the efficacy of the KRG extract compared to placebo and will be provided valuable new information about the clinical and physiological effects of the KRG extract on reduction of ILI incidence including flu and upper respiratory tract infections. The study has been pragmatically designed to ensure that the study findings can be implemented into clinical practice if KRG extract can be shown to be an effective reduction strategy in ILI incidence.

Trial registration: NCT01478009.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow diagram for study. Summary of the study flow.

Similar articles

Cited by

References

    1. Kaye M, Skidmore S, Osman H, Weinbren M, Warren R. Surveillance of respiratory virus infections in adult hospital admissions using rapid methods. Epidemiol Infect. 2006;134(4):792–798. doi: 10.1017/S0950268805005364. - DOI - PMC - PubMed
    1. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007;30(6):1158–1166. doi: 10.1183/09031936.00034407. - DOI - PubMed
    1. Camps M, Ricart S, Dimova V, Rovira N, Munoz-Almagro C, Garcia JJ, Pons-Odena M, Marcos MA, Pumarola T. Prevalence of human metapneumovirus among hospitalized children younger than 1 year in Catalonia, Spain. J Med Virol. 2008;80(8):1452–1460. doi: 10.1002/jmv.21209. - DOI - PMC - PubMed
    1. Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, McMenamin J, Fleming DM, Zambon MC. Fatal cases of influenza a in childhood. PLoS One. 2009;4(10):e7671. doi: 10.1371/journal.pone.0007671. - DOI - PMC - PubMed
    1. Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB, Bruden D, Englund JA, Anderson LJ, Lucher L. et al.Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–1290. doi: 10.1002/jmv.21790. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources